Bli medlem
Bli medlem

Du är här

2019-10-25

Xvivo Perfusion: Redeye: Xvivo Perfusion - Moving the needle

Sales came in higher than we expected in Q3 and also beat the street
expectation. We forecast sales of SEK 66.8 million and EBITDA of SEK
14.1 million Q4'19.

Read more and download the research update: http://bit.ly/2Nayvm7

Start following companies at Redeye to receive the latest equity
research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment
Banking. https://www.redeye.se/about/

-----------------------------------------------------------
https://news.cision.com/se/xvivo-perfusion/r/redeye-xvivo-perfusion--mov...

Författare Cision News

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.